High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease

Werner Robert Bezwoda Department of Medicine, Haematology/Oncology, University of the Witwatersrand, Medical School, 7 York Rodd, Parktown, 2193, Johannesburg, South Africa

Roger Dansey Department of Medicine, Haematology/Oncology, University of the Witwatersrand, Medical School, 7 York Rodd, Parktown, 2193, Johannesburg, South Africa

Abstract

Eleven patients with Hodgkin's disease relapsed from or refractory to conventional-dose chemotherapeutic regimens including MOPP and ABVD were treated by means of high-dose chemotherapy (either single agent melphalan or high-dose cyclophosphamide. VP 16 and BCNU) with bone-marrow rescue (autologous 9, allogeneic 2). Of the 11 patients treated, there were five complete and three partial remissions, with one toxic death. High-dose chemotherapy has the potential for achieving a substantial remission rate in Hodgkin's disease even after failure of conventional-dose chemotherapy.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease

Information for

Open access

Opportunities

Help and information

High-Dose Chemotherapy with Bone-Marrow Rescue for Treatment of Relapsed and Refractory Hodgkin's Disease

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature